# IND-Enabling Development of Rx100 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome.

> **NIH NIH N01** · RXBIO, INC. · 2020 · $1,524,658

## Abstract

This contract supports the development of safe and effective MCMs to mitigate and/or treat tissue injuries arising from exposure to ionizing radiation from a radiological or nuclear incident, thereby leading to a reduction in radiation-associated morbidities and mortalities.

## Key facts

- **NIH application ID:** 10241884
- **Project number:** 272201800052C-P00009-9999-1
- **Recipient organization:** RXBIO, INC.
- **Principal Investigator:** SHANNON MCCOOL
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,524,658
- **Award type:** —
- **Project period:** 2018-09-01 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10241884

## Citation

> US National Institutes of Health, RePORTER application 10241884, IND-Enabling Development of Rx100 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome. (272201800052C-P00009-9999-1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10241884. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*